Principal Indication definition

Principal Indication means with respect to (a) any IND-Ready Option Candidate Drug or IND-Ready Option Product, the Option Indication specified by AstraZeneca in the Product Development Plan for such Option Compound, and (b) any POC Option Candidate Drug or POC Option Product, the Option Indication specified in the Option Compound Development Plan, or if no such plan is agreed to by the Parties, the Targacept Option Compound Development Plan.
View Source

Examples of Principal Indication in a sentence

  • The Parties shall then agree the development plan for this Indication and appropriate milestones for this Indication, which development plan shall be incorporated into the Development Plan and which milestones for this indication shall be incorporated into Clause 11 of this Agreement and the other provisions of this Agreement shall apply to such indication as if it had always been a Principal Indication.

  • Notwithstanding anything in this Agreement to the contrary, if an IND-Ready Notice or POC Notice specifies, or Option Compound Proof of Concept is achieved, for two Option Indications, AstraZeneca shall only have a diligence obligation with respect to one Principal Indication.

  • For purposes of clarity, if prior to the Schizophrenia Expiration Date, AstraZeneca has exercised an Option for an Option Compound Candidate Drug for which Schizophrenia is a Principal Indication or AstraZeneca otherwise Commercializes an Option Compound Product for Schizophrenia there shall be no Schizophrenia Expiration Date.

  • For purposes of clarity, if prior to the Schizophrenia Expiration Date, AstraZeneca has exercised an Option for an Option Compound Candidate Drug for which Schizophrenia is a Principal Indication or AstraZeneca otherwise Commercializes an Option Compound Product for Schizophrenia, there shall be no Schizophrenia Expiration Date.

  • Otherwise, the Principal Indication for such Option Compound Candidate Drug for purposes of this Section 5.10.2(c) shall be the Option Indication that is Developed by AstraZeneca.

  • Notwithstanding anything in this Agreement to the contrary, if Option Compound Proof of Concept is achieved [********], AstraZeneca shall [********] have a diligence obligation with respect to the 5619 Principal Indication.

  • If Regulatory Approval is obtained for a TC-5619 Product for the 5619 Principal Indication in [********], AstraZeneca shall use Commercially Reasonable Efforts to (A) Commercialize such TC-5619 Product for the 5619 Principal Indication in [********] and (B) obtain Regulatory Approval for such TC-5619 Product for the 5619 Principal Indication in [********].

  • The term of the Lease shall be for _33_ (Thirty Three) years and this term may be extended at the sole discretion of the Lessor up to two times, each for a period up to 33 years (“Lease Period”).